Correspondingly, the use of LOXL2/LOXL3 inhibitor can reduce collagen oxidation and collagen crosslinking, which represents an innovative therapeutic approach for the treatment of fibrosis (Schilter et al., 2019). Here, LOXL2 is linked to fibrosis.